ASH 2025 | A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study

At ASH 2025 in Orlando, Florida, we are presenting several studies. One of them we have an oral presentation for is the ReKInDLE study. This study is based on the iberdomide, one of the new cell mod drugs. And it’s also given in combination on this ReKInDLE study in combination with carfilzomib, daratumumab, and dexamethasone. So it’s similar to the Advanced study that we presented at ASCO of 2025. In the ADVANCE study, we used daratumumab with KRd. Here, we do daratumumab with KRd. So Revlimid has been replaced by iberdomide. So the rationale behind this idea was that if you give Dara-KRd, you can have, say, 60 or so percent MRD negativity rates, and you can give patient eventually maintenance therapy that could be just single drug of lenalidomide. So if patient many years later relapsed, it wouldn’t make sense to use Revlimid for the next line of therapy. But what about reusing the carfilzomib and daratumumab and dexamethasone that worked so well for many patients in the ADVANCE study? So that led us to develop the ReKInDLE study. So replacing Revlimid for iberdomide. So reusing three drugs and changing the one that the patient relapsed off. And what we show here is that it’s a study that’s a phase two study that’s open for any prior, it’s deal of choice, newly diagnosed treatment. So you don’t have to give Dara-KRd to be eligible. You can give KOD or VOD or DARA-VOD. It’s open for any of those combinations, for any other therapy as well. But patients that go on have to have one to three prior lines of therapy. And so that means that some patients have even had a second or even a third relapse. And what we show here is that the MRD negativity rate, 10 to minus 5, is 71%. So it’s even higher than we saw with direct KOD in the newly diagnosed setting, which is remarkable. So, of course, we are wondering what would have happened if we gave this regimen for newly diagnosed patients, would that be even higher? I also think for context, to have a therapy that can give you MRD negativity 10 to minus 5 in 71% of patients, one to three prior lines, that is definitely at the same level as the bispecific antibodies. So you have another alternative. So if you’re looking at using teclistamab, daratumumab, which is what the Majestic 3 study is presenting here at this ASH meeting. Very impressive results. This ReKInDLE study has very similar results. Very, very, very efficacious. We give eight cycles of this therapy, followed by oral iberdomide. And the study has three years built in. But the plan is to have an extension for compassionate use afterwards. So that’s another option. It’s good to have options.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.